CLIA Validation of a New High Performance HPV ctDNA Assay Covering Multiple High Risk HPV Types

To develop and CLIA validate a droplet digital PCR (ddPCR) assay capable of enhancing the detection of multiple high-risk types of human papillomavirus (hrHPV) circulating tumor DNA (ctDNA) in plasma from patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC).

Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: C. Hochfelder, H. Walline, C. Bhambhani, C. Brummel, E. Sandford, R. Akhdar, K. Casper, S.B. Chinn, M.E. Heft-Neal, K. Malloy, J.L. Shah, A. Shuman, M. Spector, C.L. Stucken, F. Worden, M.E. Prince, M.L. Mierzwa, P.L. Swiecicki, M. Tewari, C. Brenner Tags: 204 Source Type: research